Boston Scientific (BSX) Stock Looks Cheap On Cash Flow While Earnings Face Doubts
Boston Scientific stock has been hit hard over the past year, yet several valuation checks now point to a company that may be trading well below its estimated worth. The question for investors is whether that pricing gap, alongside the current operational challenges, reflects opportunity or ongoing concern.
- The share price is down 56.2% over the past year, which puts Boston Scientific firmly in a reset phase in the market’s eyes.
- The recent cyberattack and lower demand for the Watchman heart implant may weigh on near term cash flows. At the same time, any progress in restoring operations and stabilising product demand can support confidence in future earnings power.
- Boston Scientific scores 5 out of 5 on a broad valuation check, and both the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently suggest the stock leans cheap.
The issue now is whether Boston Scientific’s current market price already reflects the operational setbacks and demand pressures, or if the discount to intrinsic value is too wide to ignore.
Spot opportunities across the broader market by comparing Boston Scientific’s reset with hand picked 52 high quality undervalued stocks that also combine compressed prices with solid fundamentals.Does Boston Scientific Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here uses projected cash flows to estimate what Boston Scientific stock could be worth today. Boston Scientific generated about $3.6b in free cash flow over the last twelve months, and the model assumes those cash flows keep growing rather than shrinking.
Based on those assumptions, the DCF model points to an intrinsic value of about $85 per share, which is 44.7% above the current market price. The recent cyberattack and softer Watchman demand help explain why the share price trades well below this estimate, because they raise questions about how reliable near term cash flows will be.
Overall, the cash flow based estimate suggests Boston Scientific stock appears undervalued compared with where the market currently prices it.
Our Discounted Cash Flow (DCF) analysis suggests Boston Scientific is undervalued by 44.7%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.
Does Boston Scientific Look Undervalued on Earnings?
The P/E multiple suits Boston Scientific because investors often focus on earnings for established medical equipment companies. Boston Scientific trades on a P/E of about 18.5x, which is well below the Medical Equipment industry average of roughly 27.5x and the broader peer group near 40.5x. That places the stock at a clear discount to many listed competitors on earnings.
A fair P/E for Boston Scientific, based on its growth profile, profitability, size and risk inputs, is estimated at about 30.0x. The gap between this fair ratio and the current 18.5x level indicates that the market is pricing Boston Scientific with a wide margin of safety even after factoring in current challenges. For investors who are comfortable focusing on earnings-based measures, that difference is a key part of the Boston Scientific valuation story.
On current earnings multiples, Boston Scientific stock appears undervalued relative to both these fair value estimates and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Boston Scientific Narrative: What Would Justify Today's Price?
Simply Wall St Narratives take the Boston Scientific valuation puzzle you have just seen and spell out the specific future paths for growth, margins and earnings that would make the stock look meaningfully higher or lower than today’s price. All of this is hosted on the company’s Community page. Each narrative links its number to a clear view on how Boston Scientific's growth, profitability and risks might develop, which you can revisit as new information becomes available.
Community valuation views on Boston Scientific are far apart, so it helps to see what is driving each side of the debate.
Bull case: 53% undervalued
"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons..."
Read the full Bull Case to see why Boston Scientific could be undervalued
Bear case: 7% overvalued
"However, management’s lower 2026 organic revenue guidance of 6.5% to 8% highlights that any benefit to top line growth could be uneven..."
Read the full Bear Case to see why Boston Scientific could be overvalued
Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!
The Bottom Line
For Boston Scientific, both the Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples currently point to an undervalued stock, rather than a clear value trap. The key question is whether the market is correctly discounting the impact of the cyberattack and softer Watchman demand or overcompensating for those risks. What matters most from here is how quickly Boston Scientific can stabilise cash flows and reassure investors on product demand. The valuation gap only becomes compelling if those operational issues prove manageable rather than structural.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com